-
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Wednesday, June 25, 2025 - 1:42pm | 511Read More...Nektar Therapeutics (NASDAQ:NKTR) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin. The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI)...
-
What's Going On With Viking Therapeutics Stock On Wednesday?
Wednesday, June 25, 2025 - 1:01pm | 793Read More...Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...
-
William Blair Initiates Viking With An Outperform Rating After Competitor Proves Strategy
Monday, April 30, 2018 - 4:07pm | 310Read More...The Rating William Blair analyst Andy Hsieh initiated coverage on Viking Therapeutics Inc (NASDAQ: VKTX) with an Outperform rating. The Thesis Hsieh doesn't consider the stock reflective of the potential of VK2809 and VK5211. “We are initiating coverage of Viking Therapeutics with an...
-
Analyst: FDA Letter Could Lead To 1-Year Delay For Celgene's Ozanimod
Wednesday, February 28, 2018 - 12:16pm | 365Read More...Celgene Corporation (NASDAQ: CELG) is under continued stock pressure Wednesday after the U.S. Food and Drug Administration rejected its New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis. Some bulls were undeterred by the sell-off, though. The Rating William Blair...
-
Celgene May Have Lost Positive Sentiment, But Its Growth Thesis Hasn't Gone Anywhere
Friday, October 27, 2017 - 9:21am | 365Read More...William Blair said in a note the double hit on Celgene Corporation (NASDAQ: CELG)'s Inflammation and Immunology franchise may have reversed positive sentiment, but the company's growth thesis and pipeline optionality remains intact. The firm reiterated its Outperform rating on the shares of the...
